Back to User profile » Professor Giorgio Colombo
Papers published by Professor Giorgio Colombo:
Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective
Torre E, Di Matteo S, Martinotti C, Bruno GM, Cabrino A, Fogliati EL, Giusti A, Barbieri M, Bottaro LC, Colombo GL
ClinicoEconomics and Outcomes Research 2026, 18:585328
Published Date: 1 May 2026
Cost-Effectiveness of Bivalent Prefusion F Vaccine for Prevention of Respiratory Syncytial Virus Among Older Adults in Italy
Di Matteo S, Bonanni P, Boccalini S, Di Virgilio R, Fogliati EL, Colombo GL
ClinicoEconomics and Outcomes Research 2026, 18:584975
Published Date: 9 April 2026
Health and Economic Advantages Associated With the Use of TachoSil: An Update of Systematic Review
Colombo GL, Droghetti A, Di Matteo S, Ottenjann H, Bruno GM
Therapeutics and Clinical Risk Management 2025, 21:257-271
Published Date: 1 March 2025
Economic Evaluation of Once-Weekly Insulin Icodec from Italian NHS Perspective
Torre E, Di Matteo S, Bruno GM, Martinotti C, Bottaro LC, Colombo GL
ClinicoEconomics and Outcomes Research 2024, 16:799-811
Published Date: 6 November 2024
Economic Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italy. Analysis and Perspectives
Torre E, Di Matteo S, Martinotti C, Bruno GM, Goglia U, Testino G, Rebora A, Bottaro LC, Colombo GL
ClinicoEconomics and Outcomes Research 2024, 16:773-784
Published Date: 24 October 2024
Clinical and Economic Impact of Early Diagnosis of Chronic Kidney Disease in General Practice: The Endorse Study
Pesce F, Bruno GM, Colombo GL, Di Matteo S, Maurizi AR, Mongelli V, Mele S, Narici L, Bianchi S, Bonomini M, Castellano G, De Nicola L, Gambaro G, Grandaliano G, La Manna G, Pani A, Ranghino A, Gesualdo L
ClinicoEconomics and Outcomes Research 2024, 16:547-555
Published Date: 5 August 2024
Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
Di Matteo S, Freilone R, Bruno GM, Notaro R, Moumene S, Martone N, Teruzzi C, Ciccarone A, Colombo GL
ClinicoEconomics and Outcomes Research 2024, 16:225-232
Published Date: 11 April 2024
Administrative Databases and Diagnostic Therapeutic and Assistance Paths -PDTA- in the Monitoring Treatment of Rheumatoid Arthritis: The Experience of ATS Pavia
Bruno GM, Valentino MC, Brunetti A, Di Matteo S, Begovic I, Croce E, Sakellariou G, Bugatti S, Perotti P, Vecchio S, Migliazza S, Langella R, Colombo GL
Pragmatic and Observational Research 2023, 14:29-38
Published Date: 19 April 2023
Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
Colombo GL, Valentino MC, Fabi A, Dieci MV, Caruggi M, Bruno GM, Lombardi G, Di Matteo S
Therapeutics and Clinical Risk Management 2023, 19:301-312
Published Date: 28 March 2023
Economic Burden of Non-Alcoholic Steatohepatitis (NASH) Among Diabetic Population in Italy: Analysis and Perspectives
Torre E, Di Matteo S, Bruno GM, Martinotti C, Valentino MC, Testino G, Rebora A, Bottaro LC, Colombo GL
ClinicoEconomics and Outcomes Research 2022, 14:607-618
Published Date: 14 September 2022
Cost Analysis of Platelet Transfusion in Italy for Patients with Chronic Liver Disease and Associated Thrombocytopenia Undergoing Elective Procedures
Mastrorilli G, Fiorentino F, Tucci C, Lombardi G, Aghemo A, Colombo GL
ClinicoEconomics and Outcomes Research 2022, 14:205-220
Published Date: 8 April 2022
Economic Impact of COVID-19 Lockdown on Italian NHS: Focus on Diabetes Mellitus
Torre E, Colombo GL, Di Matteo S, Martinotti C, Valentino MC, Rebora A, Cecoli F, Monti E, Galimberti M, Di Bartolo P, Gaggioli G, Bruno GM
ClinicoEconomics and Outcomes Research 2021, 13:503-518
Published Date: 14 June 2021
Utilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy
Colombo GL, Heiman F, Peduto I
Therapeutics and Clinical Risk Management 2021, 17:345-356
Published Date: 21 April 2021
Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study
Torre E, Bruno GM, Di Matteo S, Martinotti C, Valentino MC, Bottaro LC, Colombo GL
ClinicoEconomics and Outcomes Research 2020, 12:177-189
Published Date: 8 April 2020
Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study
Canonica GW, Colombo GL, Rogliani P, Santus P, Pitotti C, Di Matteo S, Martinotti C, Bruno GM
Risk Management and Healthcare Policy 2020, 13:43-53
Published Date: 22 January 2020
Cost-consequence analysis for human recombinant growth hormone (r-hGH) treatment administered via different devices in children with growth hormone deficiency in Italy
Foo J, Maghnie M, Colao A, Vlachaki I, Colombo G
ClinicoEconomics and Outcomes Research 2019, 11:525-537
Published Date: 22 August 2019
Cost-effectiveness and budget impact analysis of viscosupplementation with hylan G-F 20 for knee and hip osteoarthritis
Migliore A, Integlia D, Pompilio G, Di Giuseppe F, Aru C, Brown T
ClinicoEconomics and Outcomes Research 2019, 11:453-464
Published Date: 22 July 2019
Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative
Colombo GL, Di Matteo S, Martinotti C, Jugl SM, Gunda P, Naclerio M, Bruno GM
ClinicoEconomics and Outcomes Research 2018, 10:477-491
Published Date: 30 August 2018
Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes
Torre E, Bruno GM, Di Matteo S, Martinotti C, Oselin M, Valentino MC, Parodi A, Bottaro LC, Colombo GL
ClinicoEconomics and Outcomes Research 2018, 10:413-421
Published Date: 26 July 2018
The preventive effect on respiratory tract infections of Oscillococcinum®. A cost-effectiveness analysis
Colombo GL, Di Matteo S, Martinotti C, Oselin M, Bruno GM, Beghi GM
ClinicoEconomics and Outcomes Research 2018, 10:75-82
Published Date: 23 January 2018
Adherence in ulcerative colitis: an overview
Testa A, Castiglione F, Nardone OM, Colombo GL
Patient Preference and Adherence 2017, 11:297-303
Published Date: 22 February 2017
Economic burden of Clostridium difficile in five hospitals of the Florence health care system in Italy
Poli A, Di Matteo S, Bruno GM, Fornai E, Valentino MC, Colombo GL
Risk Management and Healthcare Policy 2015, 8:207-213
Published Date: 18 November 2015
Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting
Colombo GL, Castagna A, Di Matteo S, Galli L, Bruno G, Poli A, Salpietro S, Carbone A, Lazzarin A
Therapeutics and Clinical Risk Management 2014, 10:9-15
Published Date: 18 December 2013
Syringeless power injector versus dual-syringe power injector: economic evaluation of user performance, the impact on contrast enhanced computed tomography (CECT) workflow exams, and hospital costs
Colombo GL, Bergamo Andreis IA, Di Matteo S, Bruno GM, Mondellini C
Medical Devices: Evidence and Research 2013, 6:169-174
Published Date: 5 November 2013
Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen
Colombo GL, Di Matteo S, Maggiolo F
ClinicoEconomics and Outcomes Research 2013, 5:59-68
Published Date: 12 February 2013
Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
Aitini E, Rossi A, Morselli P, Vivorio B, Bruschi A, Bottura C, Colombo GL.
Cancer Management and Research 2012, 4:99-103
Published Date: 27 March 2012